Targeted biological therapies for Graves’ disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab
dc.contributor.author | Hegedüs, Laszlo | en_US |
dc.contributor.author | Smith, Terry J. | en_US |
dc.contributor.author | Douglas, Raymond S. | en_US |
dc.contributor.author | Nielsen, Claus H. | en_US |
dc.date.accessioned | 2011-01-31T17:36:28Z | |
dc.date.available | 2012-03-05T15:30:01Z | en_US |
dc.date.issued | 2011-01 | en_US |
dc.identifier.citation | Hegedüs, Laszlo; Smith, Terry J.; Douglas, Raymond S.; Nielsen, Claus H.; (2011). "Targeted biological therapies for Graves’ disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab." Clinical Endocrinology 74(1): 1-8. <http://hdl.handle.net/2027.42/79171> | en_US |
dc.identifier.issn | 0300-0664 | en_US |
dc.identifier.issn | 1365-2265 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/79171 | |
dc.description.abstract | Based on experience from the treatment of other autoimmune diseases and because of the limitations imposed by existing therapeutic options for Graves’ disease (GD) and thyroid-associated ophthalmopathy (TAO), rituximab (RTX) was recently proposed as a novel therapy option. Here, we summarize the rationale for using RTX; give an overview of the possible mechanisms of action; and give an account of its effects and side-effects when used in GD and TAO. Scant evidence, originating from only a few methodologically inhomogeneous studies, suggests that RTX may prolong remission for hyperthyroidism over that seen with antithyroid drugs, at least in mild GD. Furthermore, in patients with TAO, who are unresponsive to conventional immunosuppressive therapy, RTX seems efficacious. As we wait for larger-scale randomized studies, RTX, should be considered experimental and reserved for patients who do not respond favourably to conventional therapy. It is the first in what is likely to be a series of new and emerging treatments specifically targeting relevant components of the immune system. Further studies will hopefully lead to improved and better tailored, individualized therapy for GD and especially TAO. | en_US |
dc.format.extent | 157456 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.title | Targeted biological therapies for Graves’ disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes. University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Endocrinology and Metabolism, Odense University Hospital, University of Southern Denmark, Odense C, Denmark | en_US |
dc.contributor.affiliationother | Department of Ophthalmology and Visual Sciences, Kellogg Eye Center | en_US |
dc.contributor.affiliationother | Institute for Inflammation Research, Rigshospitalet, National University Hospital, DK Copenhagen, Denmark | en_US |
dc.identifier.pmid | 20455896 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/79171/1/j.1365-2265.2010.03806.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2265.2010.03806.x | en_US |
dc.identifier.source | Clinical Endocrinology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.